Loading...
NF-κB suppression→DAMPs-induced inflammation reduction
Statins reduce DAMPs-induced inflammation and inhibit T-cell activation relevant to psoriasis pathogenesis via NF-κB and Rho GTPase pathway suppression. A meta-analysis of RCTs shows improvement in disease severity scores. Evidence is clinical but effect sizes are modest and statins are not routinely used as primary psoriasis therapy.
“Statins can improve disease severity and quality of life in psoriasis patients, suggesting the potential benefits of statin therapy.”
— The Impact of Statins on Disease Severity and Quality of Life in Patients with Psoriasis: A Systematic Review and Meta-Analysis. (2024)DOI“Statin therapy is effective in lowering DAMPs-induced inflammation in psoriasis patients.”
— Atorvastatin attenuates the expression of damage-associated molecular patterns and inflammatory cytokines in patients with psoriasis. (2025)DOI“The effect of statins on psoriasis severity: a meta-analysis of randomized clinical trials.”
— The effect of statins on psoriasis severity: a meta-analysis of randomized clinical trials. (2020)DOI“The Impact of Statins on Disease Severity and Quality of Life in Patients with Psoriasis: A Systematic Review and Meta-Analysis.”
— The Impact of Statins on Disease Severity and Quality of Life in Patients with Psoriasis: A Systematic Review and Meta-Analysis. (2024)DOI“The underuse of interventions in cardiovascular prevention, such as statins, for patients with psoriasis may be the result of an insufficient evaluation.”
— Statins and psoriasis: Position statement by the Psoriasis Task Force of the European Society of Dermatology and Venerology. (2023)DOI“In psoriasis, statins enhance AA and decrease LA, consistent with the action of enhanced FADS expression in vivo.”
— Statin therapy upregulates arachidonic acid status via enhanced endogenous synthesis in patients with plaque psoriasis. (2022)DOI“Among the different treatments for psoriasis, statins have been found to reduce the severity of the disease.”
— Oral simvastatin combined with narrowband UVB for the treatment of psoriasis: A randomized controlled trial. (2021)DOI“Thus, we validate a role of galectin-7 in the pathogenesis of psoriasis, in both epidermal hyperplasia and keratinocyte-mediated inflammatory responses, and formulated a rationale for the use of statins in the treatment of psoriasis.”
— Galectin-7 downregulation in lesional keratinocytes contributes to enhanced IL-17A signaling and skin pathology in psoriasis. (2020)DOI“Lipid-lowering drugs, particularly statins, can be used to treat psoriasis with good efficacy and few side effects.”
— Current evidence on the role of lipid lowering drugs in the treatment of psoriasis. (2022)DOI“Recently, several clinical reports of other statins suggest its role on reducing the severity of psoriasis, but the available evidence on cellular/molecular level of mevastatin is unclear.”
— Regulatory Effect on Skin Differentiation by Mevastatin in Psoriasis Model Using TNF-α and IL-17 Induced HaCaT Cells (2021)DOI“Abstract 14986: A Randomized Trial of Statins to Reduce Vascular Endothelial Inflammation in Psoriasis”
— Abstract 14986: A Randomized Trial of Statins to Reduce Vascular Endothelial Inflammation in Psoriasis (2020)DOI“For instance, statins also seem beneficial in dermatitis, psoriasis, vitiligo, hirsutism, uremic pruritus, and graft-versus-host disease.”
— Therapeutic Effects of Statins: Promising drug for Topical and Transdermal Administration. (2023)DOI“Lipid pathways have been implicated in the pathogenesis of psoriasis, and some lipid-lowering drugs, such as statins, are hypothesized to have disease-modifying properties.”
— Association of Lipid-Lowering Drugs With Risk of Psoriasis: A Mendelian Randomization Study. (2023)DOI